Stocks scoring 0–25 beat the S&P 500
39.9% of the time over the next three months, since 2015.
How we measured this →
2
hedge funds
hold it · 1 added
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$44M
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGM
About GAIN THERAPEUTICS INC
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. Its lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. The…
Who's behind the signal
Every informed buyer we can see on GANX, across all three feeds.
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar.
GAIN THERAPEUTICS INC isn't in the top-10 model right now, but 2 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
2
Investors
0
New positions
1
Increasing
0
Decreasing
1
Unchanged
Price History
Loading price data...
Ctrl/⌘ + scroll or pinch to zoom · drag to measure · double-click to resetPinch to zoom · drag sideways to move through time
Return: High: Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
How much of each investor's portfolio is allocated to GAIN THERAPEUTICS INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell GAIN THERAPEUTICS INC or any security.